Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced miR-29b up-regulation, resulting in loss of transcriptional activation for several genes relevant to myeloid leukemogenesis, including DNA methyltransferases and receptor tyrosine kinases. Thus, a phase 1 trial of bortezomib and decitabine was developed. Nineteen poor-risk AML patients (median age 70 years; range, 32-84 years) enrolled. Induction with decitabine (20 mg/m2 intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m2 on days 5, 8, 12, and 15) was tolerable, but bortezomib-related neuropathy developed after repetitive cycles. Of previously untreated patients (age ≥ 65 years), 5 of 10 had CR (complete remission, n = 4) or incomplete CR (CRi, n = 1); 7 of 19 overall had CR/CRi. Pharmacodynamic analysis showed FLT3 down-regulation on day 26 of cycle 1 (P = .02). Additional mechanistic studies showed that FLT3 down-regulation was due to bortezomib-induced miR-29b up-regulation; this led to SP1 down-regulation and destruction of the SP1/NF-κB complex that transactivated FLT3. This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials. This study is registered at http://www.clinicaltrials.gov as NCT00703300.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Cited by
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance
Jacamo, R., Chen, Y., Wang, Z., Ma, W., Zhang, M., Spaeth, E. L., Wang, Y., Battula, V. L., Mak, P. Y., Schallmoser, K., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511527 · Cited by 282
Tarighat, S. S., Santhanam, R., Frankhouser, D., Radomska, H. S., Lai, H., Anghelina, M., Wang, H., Huang, X., Alinari, L., Walker, A., et al. (2016) · Leukemia · doi:10.1038/leu.2015.308 · Cited by 169
Self-citationNeaga, A., Bagacean, C., Tempescul, A., Jimbu, L., Mesaros, O., Blag, C., Tomuleasa, C., Bocsan, C., Gaman, M., & Zdrenghea, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582915 · Cited by 30
Metadata
- Authors
- Blum, W., Schwind, S., Tarighat, S. S., Geyer, S., Eisfeld, A.-K., Whitman, S., Walker, A., Klisovic, R., Byrd, J. C., Santhanam, R., Wang, H., Curfman, J. P., Devine, S. M., Jacob, S., Garr, C., Kefauver, C., Perrotti, D., Chan, K. K., Bloomfield, C. D., Caligiuri, M. A., Grever, M. R., Garzon, R., & Marcucci, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-06-21
- Volume
- 119
- Issue
- 25
- Pages
- 6025-6031
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2057652101
- Cited by
- 135
- References
- 1
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2012-03-413898
- The paper
- Blum, W., Schwind, S., Tarighat, S. S., Geyer, S., Eisfeld, A.-K., Whitman, S., Walker, A., Klisovic, R., Byrd, J. C., Santhanam, R., Wang, H., Curfman, J. P., Devine, S. M., Jacob, S., Garr, C., Kefauver, C., Perrotti, D., Chan, K. K., Bloomfield, C. D., . . . Marcucci, G. (2012). Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2012-03-413898
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.